Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330958 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL13302345 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL13302346 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL2630659 | 1.00 | MEN1 (0.38) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL22080250 | 0.81 | MEN1 (0.42) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL13360948 | 0.80 | KMT2A (0.41) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL24981405 | 0.77 | MEN1 (0.39) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL13924261 | 0.77 | MEN1 (0.39) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL28049898 | 0.77 | MEN1 (0.37) | MEN1MAPK1KMT2ACTSKNFKB1 | |
| SCHEMBL3361308 | 0.77 | MEN1 (0.37) | MEN1MAPK1KMT2ACTSKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-7935670-B2 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl- N-(1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)carboxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-7601686-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | MEN1 3909/4885MAPK1 2986/4885KMT2A 4411/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | MEN1 3911/4885MAPK1 2938/4885KMT2A 4324/4885 |
| US-20080014173-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | MEN1 4801/4885MAPK1 3159/4885KMT2A 4486/4885 |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, CTRB1 | MEN1 4820/4885MAPK1 2557/4885KMT2A 4052/4885 |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | MEN1 4820/4885MAPK1 2557/4885KMT2A 4052/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | MEN1 3909/4885MAPK1 2986/4885KMT2A 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.